TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00145847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone or Placebo
Description: Naltrexone or Placebo 50 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone or Placebo
Description: Naltrexone or Placebo 50 mg per day
Study: NCT02303431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban low dose
Description: Edoxaban low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban low dose
Description: Edoxaban low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban low dose
Description: Edoxaban low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban low dose
Description: Edoxaban low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban low dose
Description: Edoxaban low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban high dose
Description: Edoxaban high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban high dose
Description: Edoxaban high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban high dose
Description: Edoxaban high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban high dose
Description: Edoxaban high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban high dose
Description: Edoxaban high dose
Study: NCT01973309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vantictumab combined with paclitaxel
Description: Vantictumab combined with paclitaxel will be administered IV.
Study: NCT03269214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Phenytoin 5%
Description: Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
Study: NCT00936624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB07
Description: SOTB07 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB07
Description: SOTB07 200mg
Study: NCT01765959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy (CBT)
Description: Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future
Study: NCT01382719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bremelanotide
Description: Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
Study: NCT00920764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Atrasentan 0.2 mg/mL solution
Description: 10 mL oral solution, daily, 8 weeks
Study: NCT02743611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-701
Description: autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-701
Description: autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
Study: NCT00920764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25 mg Atrasentan QD
Description: 10 mL oral solution, daily, 8 weeks
Study: NCT02743611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-701
Description: autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-701
Description: autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
Study: NCT00936624

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast 10mg po, bid, 12week
Study: NCT02743611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
Study: NCT04480281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Iv
Description: Patients in the Lidocaine group received a bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
Study: NCT03110055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: anti-viral treatment for HCV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical records
Description: Medical records of patients who underwent Transarterial Chemoembolization only, in the past.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
Study: NCT01664793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 Pillars Immunization Toolkit
Description: Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
Study: NCT03429478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative application of a bluetooth enabled Headphones.
Description: A Bluetooth enabled Headphones device which is worn overhead and music can be played through it.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative application of a bluetooth enabled Headphones.
Description: A Bluetooth enabled Headphones device which is worn overhead and music can be played through it.
Study: NCT04620486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epic Best Practice Alert
Description: This is a customized Best Practice Alert created at Mass General Brigham in the institutional Epic electronic medical record system.
Study: NCT03789591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg\*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg\*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.
Study: NCT03404466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypidone Hydrochloride tablets
Description: Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypidone Hydrochloride tablets
Description: Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks
Study: NCT03932799

Intervention type: OTHER
Intervention: Prospective prior authorization (PA) with hard stops in Washington
Description: Under Washington regulatory procedures, payment for any opioid prescription billed beyond six weeks after the injury is denied unless the prescriber has submitted a checklist attesting to completion of all best practices from the regulations/guidelines.Thus, the Washington intervention is prospective and includes a hard stop subject to an insurer's decision based on regulatory authority.

Intervention type: OTHER
Intervention: Retrospective review (RR) with prescriber notification in Ohio
Description: In Ohio an automated report identifies new opioid prescriptions beyond the acute phase. Ohio Workers' Compensation pharmacy and clinical staff review the medical record at 12 weeks to determine whether best practices were met. If not, the prescriber is notified via letter, and cases are reviewed again at 16 weeks. If best practices have still not been met, the prescriber and worker are notified via letter that opioid coverage will end in 4 weeks. The Ohio program relies on retrospective chart review and communication of best practices to prescribers.
Study: NCT02638636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based exposure therapy
Description: The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
Study: NCT01206855

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy
Description: Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Postoperative Incision Care
Description: Incision cleansing, topical creams, and dressing as needed
Study: NCT01274247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Benzocaine
Description: Topical administration of a drop of benzocaine to the lingual frenulum
Study: NCT01656720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1R, 2S-methoxamine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1R, 2S-methoxamine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1R, 2S-methoxamine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01867229

Intervention type: OTHER
Intervention: observational
Description: standard of care fore patients with non metastatic breast cancer
Study: NCT03168984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0942
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use
Study: NCT02173119

Intervention type: OTHER
Intervention: MRI post-TACE
Description: Perform lipiodol delivery measurements with MRI post-TACE.
Study: NCT00545701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza virus
Description: 0.5 mL, Intramuscular
Study: NCT03609619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEVI-001
Description: Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses of Placebo will be administered twice daily, during the treatment period.
Study: NCT04031456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: Autologous PRP intra ovarian infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Platelet Free Plasma
Description: Autologous PFP intra ovarian infusion
Study: NCT00694291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02256930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: M518101 Vehicle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lauryl sulfate

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Study: NCT00962026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept given subcutaneously, dose per package labeling, once weekly.
Study: NCT01288560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced cardiac imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiac Imaging
Study: NCT04439955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: 300 mg CBD
Study: NCT03969875

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene catheter
Description: rescue catheters attached to a PCA pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 10 cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 1 cc of 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5% bupivacaine
Study: NCT00167245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 300mg/day for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills
Study: NCT04273048

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Intervention - Group 1
Description: They will be provided with a Mediterranean diet plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention - Group 1
Description: They will be provided with an exercise plan to follow.
Study: NCT02917967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Description: 1. BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.~2. Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.~A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP
Study: NCT03285932

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: post-operative stereotactic radiosurgery (SRS)
Description: For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.~Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.~Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife.

Intervention type: RADIATION
Group type: OTHER
Intervention: Whole brain radiotherapy (WBRT)
Description: For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.~RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.~For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied.
Study: NCT03006809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT), OpenBiome
Description: Delivered by colonoscopy, enema or orally (as capsules)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT), OpenBiome
Description: Delivered by colonoscopy, enema or orally (as capsules)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT), OpenBiome
Description: Delivered by colonoscopy, enema or orally (as capsules)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT), OpenBiome
Description: Delivered by colonoscopy, enema or orally (as capsules)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pretreatment antibiotics
Description: 5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pretreatment antibiotics
Description: 5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT
Study: NCT00693199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: amlodipine 5mg once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terazosin
Description: terazosin 2 mg once daily for 28 days
Study: NCT04909476

Intervention type: PROCEDURE
Intervention: Endotracheal intubation
Description: Airways management in COVID 19 patients pneumonia
Study: NCT04444856

Intervention type: DRUG
Intervention: Eptacog alfa (activated)
Description: The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
Study: NCT00920764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75 mg Atrasentan QD
Description: 10 mL oral solution, daily, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.75 mg Atrasentan QD
Description: 10 mL oral solution, daily, 8 weeks
Study: NCT00693199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine plus terazosin
Description: amlodipine 5 mg plus terazosin 2 mg once daily for 28days
Study: NCT05529563

Intervention type: PROCEDURE
Intervention: LSG
Description: LSG
Study: NCT03436355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The Active school study was a 10-month randomized controlled trial.The weekly interventions were 2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework.
Study: NCT03871855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1702
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1702
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1702
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1702
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Administered IV
Study: NCT03948230

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Salt with / without water
Description: Drinks with and without a salt containing capsule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Salt with / without water
Description: Drinks with and without a salt containing capsule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Salt with / without water
Description: Drinks with and without a salt containing capsule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salt with / without water
Description: Drinks with and without a salt containing capsule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salt with / without water
Description: Drinks with and without a salt containing capsule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salt with / without water
Description: Drinks with and without a salt containing capsule
Study: NCT02848079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined TAS-102 and TAS-OX
Description: Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
Study: NCT02023658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pMTCT systems analysis and improvement
Description: Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
Study: NCT03902678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS guided fine needle aspiration of portal vein thrombus
Description: endoscopic ultrasound guided fine needle aspiration of portal vein thrombus which did not fulfill criteria of malignancy by imaging technique